AstraZeneca 'ahead of schedule' in development of personalised medicines
This article was originally published in Clinica
Pharma giant AstraZeneca has highlighted the importance of biomarkers, beating a self-imposed target of having half of the product candidates in its portfolio associated with patient stratification tools by about three years.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.